Evidence map›Paper›PMID 38846534›Full record

ArticleBrain communications2024

Personality and quality-of-life improvement after apomorphine infusion in Parkinson's disease.

Mathilde Boussac, Estelle Harroch, Christel Barthelemy, Fabienne Ory-Magne, Clémence Leung, Margherita Fabbri, Christophe Arbus, Christine Brefel-Courbon

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06080399 (Could Psycho-bio-social Context and Personality be a Predictive Factor of Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease Patients? - PERSO-PERF Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06080399 completednot on this map

Could Psycho-bio-social Context and Personality be a Predictive Factor of Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease Patients? - PERSO-PERF Study

TypeobservationalSponsorUniversity Hospital, ToulouseRan2024 to 2026Enrolled70ConditionsParkinson DiseaseArmsContinuous subcutaneous apomorphine infusion (CSAI)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mathilde BoussacToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.ORCID https://orcid.org/0000-0002-3532-6743
Estelle HarrochDepartment of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), 31024 Toulouse, NS-PARK/FCRIN Network, France.
Christel BarthelemyDepartment of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), 31024 Toulouse, NS-PARK/FCRIN Network, France.
Fabienne Ory-MagneToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.
Clémence LeungDepartment of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), 31024 Toulouse, NS-PARK/FCRIN Network, France.
Margherita FabbriToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.
Christophe ArbusToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.
Christine Brefel-CourbonToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, 31024 Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People with Parkinson's disease with motor fluctuations can be treated by continuous subcutaneous apomorphine infusion (CSAI) to reduce their symptoms. Nonetheless, factors are lacking to predict patients' quality-of-life amelioration after CSAI. This pilot study aimed to evaluate associations between personality dimensions and quality-of-life improvement after 6 months of CSAI. Thirty-nine people with Parkinson's disease awaiting CSAI were included. Linear regression models between 'Temperament and Character Inventory' personality dimensions at baseline and percentage of change in Parkinson's Disease Questionnaire-39 scores after 6 months of CSAI were realized (

Indexed as

precision medicineTemperament and Character Inventorytherapeutics

Identifiers

PMID38846534
PMCPMC11154139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.